Abstract
Adoptive cell therapies are showing very promising results in the fight against cancer. However, these therapies are expensive and technically challenging in part due to the need of a large number of specific T cells, which must be activated and expanded in vitro. Here we describe a method to activate primary human T cells using a combination of nanostructured surfaces functionalized with the stimulating anti-CD3 antibody and the peptidic sequence arginine-glycine-aspartic acid, as well as costimulatory agents (anti-CD28 antibody and a cocktail of phorbol 12-myristate 13-acetate, ionomycin, and protein transport inhibitors). Thus, we propose a method that combines nanotechnology with cell biology procedures to efficiently produce T cells in the laboratory, challenging the current state-of-the-art expansion methodologies.
Original language | English |
---|---|
Pages (from-to) | 5899-5904 |
Number of pages | 6 |
Journal | Nano Letters |
Volume | 18 |
Issue number | 9 |
DOIs | |
State | Published - 12 Sep 2018 |
Keywords
- CD3/CD28
- Nanostructures
- PMA/ionomycin
- T cells
- integrins